Physician profile
Holly E Harmon
NPI 1013579820
$3,647.65
in general payments reported to CMS, 2019-2025
22 companies · $1,046 in 2025
The $1,046 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $301 · 2022: $309 · 2023: $820 · 2024: $1,171 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,993 · Education: $45.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,992.57 |
| Education | $45.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $879.24 | 2021-2025 | Abilify Maintena, Rexulti, Nuedexta |
| Abbvie INC. | $661.15 | 2023-2025 | |
| Alkermes, INC. | $339.76 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $271.30 | 2023-2025 | Caplyta |
| Lundbeck LLC | $221.01 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $171.45 | 2023-2025 | Ingrezza, Ongentys |
| Harmony Biosciences LLC | $170.16 | 2022-2024 | Wakix |
| Axsome Therapeutics, INC. | $163.28 | 2024-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $101.74 | 2024-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $97.43 | 2025 | Fanapt |
| Lilly USA, LLC | $92.37 | 2022-2025 | Mounjaro, Trulicity, Jardiance |
| Janssen Pharmaceuticals, INC | $79.94 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $73.14 | 2024-2025 | Austedo Xr, Uzedy |
| Amgen INC. | $61.02 | 2023-2024 | Repatha, Otezla, Evenity |
| Collegium Pharmaceutical, INC. | $49.52 | 2025 | Jornay Pm |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $47.21 | 2023-2024 | Jornay Pm |
| Corium, LLC | $38.71 | 2024-2025 | Azstarys |
| Avanir Pharmaceuticals, INC. | $38.21 | 2021 | |
| Mylan Specialty L.P. | $31.11 | 2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.80 | 2024 | Jardiance, Tradjenta |
| Viatris Specialty LLC | $19.88 | 2025 | Yupelri |
| Exact Sciences Corporation | $18.22 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.